SynthesisHuman cell2011
MDM2 SNP309 is associated with endometrial cancer susceptibility: a meta-analysis.
Synthesis in Human cell, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 12 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 12 syntheses or guidelines pooled it.
- Association between genetic polymorphisms and endometrial cancer risk: a systematic review.Journal of medical genetics · 2020Pooled it
- Correlation between MDM2 T309G single nucleotide polymorphism and esophageal cancer susceptibility: An updated meta-analysis.Thoracic cancer · 2020Pooled it
- Pooled it
- Murine Double Minute 2 SNP T309G Polymorphism and Urinary Tract Cancer Risk: A Meta-Analysis.Medicine · 2016Pooled it
- MDM2 rs2279744 polymorphism and endometrial cancer: a meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- MDM2 SNP309 is an ethnicity-dependent risk factor for digestive tract cancers.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- Analyzing association of the XRCC3 gene polymorphism with ovarian cancer risk.BioMed research international · 2014Pooled it
- Polymorphisms in the MDM2 gene and risk of malignant bone tumors: a meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- MDM2 SNP309 polymorphism contributes to endometrial cancer susceptibility: evidence from a meta-analysis.Journal of experimental & clinical cancer research : CR · 2013Pooled it
- Analyze association of the progesterone receptor gene polymorphism PROGINS with ovarian cancer risk.Molecular biology reports · 2013Pooled it
- The MDM2 309T>G polymorphism and ovarian cancer risk: a meta-analysis of 1534 cases and 2211 controls.PloS one · 2013Pooled it
- Association of MDM2 SNP309 variation with lung cancer risk: evidence from 7196 cases and 8456 controls.PloS one · 2012Pooled it
- Analysis of the association between the XRCC2 rs3218536 polymorphism and ovarian cancer risk.Archives of medical science : AMS · 2020Article
- Common genetic variants in the TP53 pathway and their impact on cancer.Journal of molecular cell biology · 2019Review
- Negative selection maintains transcription factor binding motifs in human cancer.BMC genomics · 2016Article
- SNP55, a new functional polymorphism of MDM2-P2 promoter, contributes to allele-specific expression of MDM2 in endometrial cancers.BMC medical genetics · 2015Article
- Association between murine double minute 2 T309G polymorphism and risk of liver cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Genetic variants and mutations of PPM1D control the response to DNA damage.Cell cycle (Georgetown, Tex.) · 2013Article
- Ewing Sarcoma: influence of TP53 Arg72Pro and MDM2 T309G SNPs.Molecular biology reports · 2013Article
- Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer.Oncology reports · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epidemiological studies have investigated the association between MDM2 promoter SNP 309 (T/G) and endometrial cancer susceptibility. However, the results are still controversial. To obtain a more precise estimate of the relationship, we conducted a meta-analysis of 1,001 cases and 1,889 controls from 6 published case-control studies (one of five articles contains two studies) to estimate the effect of SNP309 on endometrial cancer risk. The strength of association between MDM2 SNP309 and endometrial cancer susceptibility was assessed by calculating pooled odds ratios (ORs) with 95% confidence intervals (CIs). When all the eligible studies were pooled in the meta-analysis, we found that elevated endometrial cancer risk was significantly associated with GG variant genotype, however, heterozygous genotype TG seemed to be only a minor modifier on endometrial cancer risk (for GG vs. TT, OR = 1.54, 95% CI = 1.21-1.95, P = 0.0004; for TG vs. TT, OR = 0.96, 95% CI = 0.81-1.14, P = 0.66; for dominant model, OR = 1.09, 95% CI = 0.93-1.29, P = 0.29; for recessive model, OR = 1.65, 95% CI = 1.33-2.04, P < 0.00001). Overall, the meta-analysis suggested that the GG genotype of MDM2 SNP309 was significantly associated with the increased endometrial cancer risk.
Indexed as
Identifiers
21547352What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.